Ruxolitinib cream for vitiligo: evidence and limits

Ruxolitinib cream is the first FDA-approved drug intended to improve repigmentation in nonsegmental vitiligo. The U.S. indication covers adults and adolescents 12 years and older, with treatment limited to affected areas up to 10% of body surface area [1][2]. It is not an approval for every white patch or every type of vitiligo.

In two phase 3 trials, roughly 30% of participants assigned to ruxolitinib cream reached at least 75% improvement in the facial Vitiligo Area Scoring Index at week 24. The vehicle groups reached that endpoint less often [3]. This is meaningful evidence of facial repigmentation for some patients, but it is not a universal response and it does not mean that 75% of the entire body repigmented.

What did the FDA approve?

Vitiligo is an autoimmune disorder in which melanocytes are lost from affected skin. Ruxolitinib inhibits JAK1 and JAK2 signaling [1]. The topical formulation is labeled for nonsegmental vitiligo, the more common pattern in which patches often occur on both sides of the body [1][2].

The boundary matters. A pale or white patch can also reflect post-inflammatory pigment change, infection, chemical exposure, scarring, or another condition. Ruxolitinib response is not a diagnostic test, and an image alone may not distinguish these causes.

The label specifies twice-daily application to affected areas up to 10% of body surface area and limits the amount used [1]. Mentioning the studied regimen explains the evidence; it is not a personal instruction. Age, diagnosis, distribution, medical history, and other treatment all affect whether the label applies.

What did TRuE-V1 and TRuE-V2 measure?

TRuE-V1 and TRuE-V2 enrolled 674 people aged 12 years or older with nonsegmental vitiligo affecting no more than 10% of total body surface area. Participants applied ruxolitinib 1.5% cream or vehicle for 24 weeks. All participants could use ruxolitinib cream for another 28 weeks [3]. The trials were funded by Incyte, and several authors were company employees or reported financial relationships.

The primary endpoint was F-VASI75 at week 24. It represents at least a 75% improvement from baseline in the facial Vitiligo Area Scoring Index.

Both replicate trials favored ruxolitinib cream [3]. The table also shows why response should not be described as certain. About seven in ten treated participants had not reached the primary facial endpoint at week 24.

The comparison after week 24 is different because the vehicle groups crossed over to active treatment. Continued improvement through week 52 is useful for understanding time to response, but the later period is not the same randomized vehicle comparison used for the primary endpoint [3].

Why can repigmentation take months?

Repigmentation requires more than a temporary change in redness. Melanocyte activity and migration into depigmented skin take time, and body sites differ in their capacity to regain pigment. The FDA specifically notes that a satisfactory response may require treatment for longer than 24 weeks [2]. That statement sets expectations; it does not promise that continued use will eventually work for everyone.

The face generally responded more readily in the pivotal program than many acral sites such as hands and feet [3]. A facial endpoint therefore should not be transferred to every body area.

A 2026 long-term extension report studied randomized withdrawal or continuation after response [4]. It adds evidence about maintenance questions, but it should not be read as proof that one maintenance approach applies to all patients. Disease activity, response depth, treated area, and other therapies can differ.

Safety evidence and label warnings

Through week 52 in TRuE-V1 and TRuE-V2, the most frequent events included application-site acne, nasopharyngitis, and application-site itching [3]. A later integrated analysis followed trial exposure through 104 weeks and reported no serious adverse events that investigators assessed as treatment related, while recording rare serious infections, malignancies, and thromboembolic events in the pooled dataset [5]. The analysis included Incyte employees and company funding disclosures.

Those data are reassuring within the studied population and exposure, but rare-event interpretation has limits. Open-label exposure, selected trial participants, and finite follow-up cannot prove that a serious event will never occur.

The FDA prescribing information carries a boxed warning covering serious infections, mortality, malignancy, major cardiovascular events, and thrombosis [1]. Some of that warning language comes from oral JAK-inhibitor experience in other populations. Topical exposure is different, but the correct conclusion is to follow the topical label rather than dismiss it.

The label also advises against combining the cream with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants [1]. Infection history, immune status, pregnancy or lactation, and other medication belong in the clinical review.

What the evidence does not establish

• The trials do not show that every white patch is vitiligo.
• F-VASI75 is a facial outcome, not a full-body percentage claim.
• There was no direct randomized comparison with narrowband UVB, topical corticosteroids, or topical calcineurin inhibitors in the pivotal trials.
• Results in disease affecting up to 10% body surface area should not be generalized to more extensive disease.
• Longer follow-up improves safety knowledge but cannot eliminate uncertainty about rare outcomes.
• Company-sponsored trials can still be informative; sponsorship and author relationships should remain visible when weighing the findings.

Bottom line

Ruxolitinib cream has randomized evidence and an FDA indication for nonsegmental vitiligo in people 12 years and older within the label's body-surface limit [1][2][3]. About 30% of treated participants reached the primary facial repigmentation endpoint at week 24 in two replicate trials, compared with 7.4% and 11.4% using vehicle [3].

The response can continue to evolve beyond six months, but improvement is neither immediate nor assured. Facial outcomes should not be applied to every body site, and topical use does not erase the prescribing information's safety warnings.

This article is for informational purposes and does not constitute medical advice. Vitiligo diagnosis and treatment should be directed by a board-certified dermatologist.